Join KBI Biopharma at BioJapan 2026 to discover how integrated development, advanced in silico modeling, and manufacturing expertise can help solve complex biologics challenges and accelerate your path to clinic and market.
From cell line and process development to analytical services and cGMP manufacturing, KBI combines deep scientific expertise with advanced mammalian and microbial platforms. Our predictive in silico capabilities add earlier insight into molecule behavior, helping development teams reduce experimentation, anticipate potential risks, and make more informed development decisions.
Schedule a meeting >>
Meet with the KBI Biopharma Team:
Integrated Solutions: Move your biologic forward with integrated support from cell line development through process development, analytical services, formulation, and cGMP manufacturing. One partner. Integrated expertise.
Predictive In Silico Capabilities: Gain earlier insight into your molecule with molecular modeling designed to identify potential physicochemical liabilities before extensive experimental development. These insights can help inform downstream process, formulation, and high-concentration UF/DF strategies.
Complex Biologics Expertise: From bispecific antibodies and Fc-fusion proteins to other challenging modalities, KBI combines advanced scientific capabilities with practical development strategies to address purification, stability, scalability, and manufacturability challenges.
Expert Consultation: Meet with KBI scientists and development experts to discuss your molecule, identify potential development risks, and explore strategies for reaching your next clinical or commercial milestone.
Stop by the KBI booth #D16 to meet our experts, explore our in silico capabilities, and discuss your program, or book a one-on-one meeting with our team.
David Brown, Associate Director, Downstream Process Development
Leveraging In Silico Protein Modeling to Accelerate Downstream Process and High-Concentration UF/DF Development
October 7, 2026 | 10:55–11:25 | Presentation Stage B
Discover how in silico protein modeling can identify molecule-specific risks earlier, inform downstream and UF/DF development, and reduce reliance on iterative experimentation.
About KBI Biopharma:
KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of our 1400+ client partners, we work closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, we help clients advance drug candidates into the clinic and beyond.
Learn more about KBI Biopharma >>
BioJapan 2026 celebrates the 40th anniversary of Asia’s premier bio-industry partnering event, bringing together the global biotech community for three days of exhibitions, seminars, and partnering. The event attracts professionals across pharma, biotech, drug discovery, academia, and CDMO services, with a strong concentration of business development, licensing, and R&D leaders seeking new technologies, services, and collaboration opportunities. In 2025, BioJapan and its co-located events welcomed more than 22,000 visitors and over 3,000 partnering participants.